Venoocclusive disease due to chemotherapy for pediatric acute lymphoblastic leukemia is associated with increased levels of plasminogen-activator inhibitor-1

Pediatr Blood Cancer. 2018 Jun;65(6):e26963. doi: 10.1002/pbc.26963. Epub 2018 Jan 19.

Abstract

We describe three cases of sinusoidal obstruction syndrome/venoocclusive disease (SOS) in pediatric patients with acute lymphoblastic leukemia (ALL). All three episodes occurred during or just after the induction or reinduction phase of treatment based on prednisone/dexamethasone, vincristine, daunorubicin, and pegylated-l-asparaginase. SOS episodes were categorized as mild/moderate and resolved in 7, 10, and 16 days using supportive measures or defibrotide therapy. In all three episodes, the clinical diagnosis of SOS was associated with a significant increase in plasminogen-activator inhibitor-1 (PAI-1) that reduced with patient clinical improvement. PAI-1 warrants study as a diagnostic marker for SOS in ALL.

Keywords: acute lymphoblastic leukemia; plasminogen-activator inhibitor-1 (PAI-1); sinusoidal obstructive syndrome; venoocclusive disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Hepatic Veno-Occlusive Disease / diagnosis*
  • Hepatic Veno-Occlusive Disease / metabolism
  • Humans
  • Male
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Prognosis

Substances

  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human